BI
BIEL.US Bioelectronics Corp
- Market cap
- USD 7.41M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is BIEL.US undervalued?
Graham numberThe Graham number of Bioelectronics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bioelectronics Corp fundamental analysis
No fundamental analysis for Bioelectronics Corp yet.
Bioelectronics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bioelectronics Corp
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-fr…
Full company profileBioelectronics Corp financial statements
Bioelectronics Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.09M | 1.76M | 1.05M | 942K | 830K | 1.61M | 707K | 715K | 496K | 511K |
| Gross Profit | 1.26M | 996K | 355K | 529K | 506K | 796K | 487K | 466K | 364K | 433K |
| Operating Income | -1.40M | -1.36M | -2.04M | -1.33M | -1.05M | -154K | -343K | -274K | -393K | 81.3K |
| EBITDA | -1.35M | -1.29M | -2.01M | -1.33M | -1.03M | 162K | -343K | -274K | -393K | 81.3K |
| Net Income | -2.11M | -2.12M | -2.99M | -2.33M | -1.16M | -290K | -785K | -723K | -931K | -532K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 714K | 503K | 469K | 345K | 425K | 83.9K | 250K | 144K | 43.3K | 142K |
| Total Liabilities | 10.5M | 11.2M | 13.5M | 14.9M | 15.5M | 15.2M | 16.0M | 16.6M | 17.5M | 18.1M |
| Shareholders' Equity | -9.76M | -10.7M | -13.0M | -14.6M | -15.1M | -15.1M | -15.8M | -16.5M | -17.4M | -17.9M |
| Cash & Short-term Investments | 5.77K | 8.89K | 92.9K | 46.2K | 110K | 925.00 | 45.0K | 4.69K | 7.87K | 3.51K |
| Total Debt | 9.77M | 10.2M | 12.0M | 12.8M | 13.2M | 13.3M | 14.1M | 14.8M | 15.5M | 16.3M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.31M | -869K | -1.35M | -716K | -528K | -320K | -479K | -336K | -164K | -151K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 0.00 | 1.00 | 3.00 | 0.00 |
| Free Cash Flow | -1.31M | -869K | -1.35M | -716K | -528K | -320K | -479K | -336K | -164K | -151K |
| Ratios | ||||||||||
| ROA | -295.2% | -421.1% | -637.2% | -674.2% | -272.8% | -345.5% | -313.7% | -500.6% | -2,148.0% | -374.0% |
| Net Profit Margin | -100.8% | -120.1% | -285.7% | -246.9% | -139.8% | -18.0% | -111.0% | -101.1% | -187.6% | -104.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bioelectronics Corp dividends
Bioelectronics Corp has not paid dividends in the last 10 fiscal years.
Who owns Bioelectronics Corp
Ownership data of Bioelectronics Corp is not available yet.
Bioelectronics Corp company profile
- Company name
- Bioelectronics Corp
- Ticker
- BIEL.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 4539 Metropolitan Court, Frederick, MD, United States, 21704
- Phone
- 301 874 4890
- Website
- bielcorp.com
About Bioelectronics Corp
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. It sells its products to wholesale distributors, hospitals and clinics, and consumers. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.
Bioelectronics Corp management
3- Mr. Andrew J. WhelanFounder · born 1942
- Ms. Kelly A. WhelanCEO, President, Treasurer & Executive Director
- Mr. John R. MartinezSecretary